Abstracts

IMPAIRMENT OF TYPE I/III IFN RESPONSE IN THE UPPER AIRWAYS OF SARS-CoV-2 PATIENTS

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most severe public healthcare concern. Interferon (IFN) represents a critical, first-line defense to viral infection and injury as part of innate immunity. Therefore, in order to provide additional insights to the pathogenesis of SARS-CoV-2, we delineated IFN signatures in the upper respiratory tract of 2019-nCoV…

NANOPARTICLE-DCs RESTORE CYTOTOXIC MEMORY-LIKE NK CELLS IN CHRONIC HIV PATIENTS

Cytotoxic CD16+ Natural Killer (NK) cells become dysfunctional in HIV-1 chronically infected individuals even after antiretroviral therapy initiation, preventing effective elimination of HIV-1 infected cells. Previous studies suggest that activated dendritic cells (DC) stimulate NK and might be useful for therapeutic purposes. However, DCs from chronic HIV-1 patients can also be unresponsive to adjuvant stimulation.…

DUAL-ANTIGEN COVID-19 VACCINATION WITH ORAL BOOST PROTECTS NHP FROM VIRAL CHALLENGE

To address the need for an efficacious COVID-19 vaccine suitable for world-wide distribution, we have developed a dual-antigen vaccine incorporating genes for a modified SARS-CoV-2 spike protein (S-Fusion) and the viral nucleocapsid protein (N) with an Enhanced T-cell Stimulation Domain (N-ETSD) with the potential to increase MHC class I/II responses. The adenovirus serotype 5 platform…

BINDING SIGNATURES AND CROSS-REACTIVITY IN THE SARS-CoV-2 IMMUNE RESPONSE

Mounting evidence indicates that antibodies generated during SARS-CoV-2 infection are correlates of protection. Antibodies targeting Spike (S) on the viral surface have been shown to neutralize the virus. However, the full repertoire of neutralizing and non-neutralizing antibodies against SARS-CoV-2, as well as cross-reactivity between SARS-CoV-2 and other circulating (CoVs), remains unclear. We sought to profile…